Mucositis Drug Rejection Sends Galera Into Tailspin
Workforce Slashed By 70%
Galera's stock has cratered after the US FDA issued a complete response letter for avasopasem manganese for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.
